Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Line 115: | Line 115: | ||
|style="background-color:#deebf7"|[[Thymoma]] | |style="background-color:#deebf7"|[[Thymoma]] | ||
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms''' | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms and Myelodysplastic Syndromes''' |
|- | |- | ||
− | |rowspan= | + | |rowspan=8 style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|thumb|upright=0.4|center]] |
− | |rowspan= | + | |rowspan=8|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> |
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]] | |style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]] | ||
|- | |- | ||
Line 126: | Line 126: | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome]] | |style="background-color:#fee0d2"|[[Hypereosinophilic syndrome]] | ||
+ | |- | ||
+ | |style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]] | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Myelofibrosis]] | |style="background-color:#fee0d2"|[[Myelofibrosis]] |
Revision as of 20:06, 9 October 2017
Please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
Peter C. Yang, MD Boston, MA Twitter: Hem_Onc |
Deputy Editor
Jeremy L. Warner, MD, MS Nashville, TN Twitter: Hemoncwarner |